Market Overview:
The global 2-valent HPV vaccine (2vHPV) market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of HPV infections, rising demand for preventive vaccines, and technological advancements in the field of vaccine development. Based on type, the global 2-valent HPV vaccine (2vHPV) market can be segmented into HPV16 and HPV18. The HPV16 segment is expected to account for a larger share of the market than the HPV18 segment during the forecast period. This can be attributed to factors such as increased awareness about cervical cancer caused by HPVs 16 and 18 among women worldwide and rising incidence rates of these types of cancer. Based on application, the global 2-valent HPV vaccine (2vHPV) market can be divided into 9-16 years old, 16-20 years old, 20-26 years old, 26-45 years old segments. The 9-16 year olds segment is projected to register highest CAGR during 2018–2030 owing high unmet needs in developing countries across regions such as Asia Pacific and Latin America followed by Europe & North America region respectively .Whereas ,the older age group are more prone towards acquiring chronic diseases such as cervical cancer so that 26 – 45 year olds age group are anticipated witness significant growth over next decade across all regions .
 Industry Outlook.svg)
Product Definition:
The 2-valent HPV vaccine (2vHPV) is a vaccine that protects against two types of human papillomavirus (HPV), HPV 16 and HPV 18. The 2vHPV is important because it can help protect people from getting cancer caused by HPV 16 and 18.
HPV16:
Human Papillomavirus (HPV)16 is a subtype of HPV that causes nearly 70% of cervical cancer cases and 50% of vulvar cancer cases. The other types are 14 and 18, which cause skin cancers. There are more than 100 strains of HPV out there, with different proteins in them. Some HPVs don’t even have the ability to cause diseases; some can only make cells look abnormal and others can actually lead to disease development.
HPV18:
HPV18 is a subtype of high-risk human papillomavirus (HPV). The presence of an 18th subtype was first reported in 2015. It was found to be the same as that previously identified as HPVs 6 & 11, which are usually responsible for causing cervical cancer in women. However, it also causes vulvar and vaginal cancers in women.
Application Insights:
9-16 years old application segment held the largest share of more than 60.0% in 2017. This is due to high prevalence of HPV infection among children below 9 years and above 16 years age groups across the globe. Moreover, increasing awareness about 2vHPV vaccine amongst parents is expected to boost demand for this product over the forecast period.
The 26-45 year olds age group accounted for a significant share in 2017 owing to rising incidence of cancer caused by 2vHPV infections across this demographic globally, particularly cervical cancer which has become one of the most common cancers amongst women aged 45 years and above since past few decades due to widespread availability.
Regional Analysis:
North America dominated the global 2-valent HPV vaccine market in 2017. This is attributed to the presence of a large target population, high awareness levels coupled with government initiatives and support from healthcare professionals and parents. In addition, increasing incidence of cervical cancer has led to an increase in demand for preventive measures such as vaccination against various infectious diseases including HPV. According to CDC’s National Center for Health Statistics (NCHS), between 2010 and 2014, an estimated 671 females were diagnosed with invasive cervical cancer; this number is expected to grow substantially over the next few years due to lack of screening programs across U.S.
Growth Factors:
- Increasing incidence of HPV infections: The increasing incidence of HPV infections is the major growth driver for 2-valent HPV vaccine market. According to the Centers for Disease Control and Prevention (CDC), approximately 79 million Americans are infected with HPV and about 14 million people become newly infected every year. This high prevalence of HPV infection is expected to drive the demand for 2-valent HPV vaccines in the coming years.
- Growing awareness about benefits of vaccination: There is a growing awareness among people about the benefits of vaccination, which is expected to boost demand for 2-valent HP vaccines in the coming years. In addition, various government and non-government organizations are promoting vaccination against various diseases including HPV, which is likely to fuel growth of this market in near future.
- Technological advancements in vaccine development: The technological advancements in vaccine development are another key factor driving growth of 2vHPV market globally. Various pharmaceutical companies are investing heavily in research and development activities to develop better and more effective vaccines against different types of viruses including HPVs, which is likely to create new opportunities for players operating in this market over next few years..
Scope Of The Report
Report Attributes
Report Details
Report Title
2-valent HPV Vaccine (2vHPV) Market Research Report
By Type
HPV16, HPV18
By Application
9-16 Years Old, 16-20 Years Old, 20-26 Years Old, 26-45 Years Old
By Companies
GSK, MSD, Beijing Wantai Biology Pharmaceutical Industry Limited, Serum Institute of India, Walvax, GSK
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
195
Number of Tables & Figures
137
Customization Available
Yes, the report can be customized as per your need.
Global 2-valent HPV Vaccine (2vHPV) Market Report Segments:
The global 2-valent HPV Vaccine (2vHPV) market is segmented on the basis of:
Types
HPV16, HPV18
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
9-16 Years Old, 16-20 Years Old, 20-26 Years Old, 26-45 Years Old
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- MSD
- Beijing Wantai Biology Pharmaceutical Industry Limited
- Serum Institute of India
- Walvax
- GSK
 Market Overview.svg)
Highlights of The 2-valent HPV Vaccine (2vHPV) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HPV16
- HPV18
- By Application:
- 9-16 Years Old
- 16-20 Years Old
- 20-26 Years Old
- 26-45 Years Old
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the 2-valent HPV Vaccine (2vHPV) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
2-valent HPV vaccine is a vaccine that protects against two types of HPV: 16 and 18. It is recommended for people aged 9 to 26 years who have not yet been exposed to either type of HPV.
Some of the major companies in the 2-valent hpv vaccine (2vhpv) market are GSK, MSD, Beijing Wantai Biology Pharmaceutical Industry Limited, Serum Institute of India, Walvax, GSK.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 2-valent HPV Vaccine (2vHPV) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 2-valent HPV Vaccine (2vHPV) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 2-valent HPV Vaccine (2vHPV) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the 2-valent HPV Vaccine (2vHPV) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global 2-valent HPV Vaccine (2vHPV) Market Size & Forecast, 2018-2028
4.5.1 2-valent HPV Vaccine (2vHPV) Market Size and Y-o-Y Growth
4.5.2 2-valent HPV Vaccine (2vHPV) Market Absolute $ Opportunity
Chapter 5 Global 2-valent HPV Vaccine (2vHPV) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Type
5.2.1 HPV16
5.2.2 HPV18
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global 2-valent HPV Vaccine (2vHPV) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Applications
6.2.1 9-16 Years Old
6.2.2 16-20 Years Old
6.2.3 20-26 Years Old
6.2.4 26-45 Years Old
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global 2-valent HPV Vaccine (2vHPV) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America 2-valent HPV Vaccine (2vHPV) Analysis and Forecast
9.1 Introduction
9.2 North America 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Type
9.6.1 HPV16
9.6.2 HPV18
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Applications
9.10.1 9-16 Years Old
9.10.2 16-20 Years Old
9.10.3 20-26 Years Old
9.10.4 26-45 Years Old
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe 2-valent HPV Vaccine (2vHPV) Analysis and Forecast
10.1 Introduction
10.2 Europe 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Type
10.6.1 HPV16
10.6.2 HPV18
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Applications
10.10.1 9-16 Years Old
10.10.2 16-20 Years Old
10.10.3 20-26 Years Old
10.10.4 26-45 Years Old
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific 2-valent HPV Vaccine (2vHPV) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Type
11.6.1 HPV16
11.6.2 HPV18
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Applications
11.10.1 9-16 Years Old
11.10.2 16-20 Years Old
11.10.3 20-26 Years Old
11.10.4 26-45 Years Old
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America 2-valent HPV Vaccine (2vHPV) Analysis and Forecast
12.1 Introduction
12.2 Latin America 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Type
12.6.1 HPV16
12.6.2 HPV18
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Applications
12.10.1 9-16 Years Old
12.10.2 16-20 Years Old
12.10.3 20-26 Years Old
12.10.4 26-45 Years Old
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) 2-valent HPV Vaccine (2vHPV) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Type
13.6.1 HPV16
13.6.2 HPV18
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) 2-valent HPV Vaccine (2vHPV) Market Size Forecast by Applications
13.10.1 9-16 Years Old
13.10.2 16-20 Years Old
13.10.3 20-26 Years Old
13.10.4 26-45 Years Old
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 2-valent HPV Vaccine (2vHPV) Market: Competitive Dashboard
14.2 Global 2-valent HPV Vaccine (2vHPV) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 MSD
14.3.3 Beijing Wantai Biology Pharmaceutical Industry Limited
14.3.4 Serum Institute of India
14.3.5 Walvax
14.3.6 GSK
